Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C25H24N3O8S2.Na |
| Molecular Weight | 581.593 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].COC1=CC2=C(C=C1)N(C(=N2)[S+]([O-])CC3=NC=C(C)C(OC)=C3C)S(=O)(=O)C4=CC=C(OCC([O-])=O)C=C4
InChI
InChIKey=VHTOWLOOYYGTNQ-UHFFFAOYSA-M
InChI=1S/C25H25N3O8S2.Na/c1-15-12-26-21(16(2)24(15)35-4)14-37(31)25-27-20-11-18(34-3)7-10-22(20)28(25)38(32,33)19-8-5-17(6-9-19)36-13-23(29)30;/h5-12H,13-14H2,1-4H3,(H,29,30);/q;+1/p-1
Allergan was developing the proton pump inhibitor AGN-201904 as an enteric-coated formulation for the treatment of gastric ulcer disease. AGN-201904 is a slowly absorbed, acid-stable pro-proton pump inhibitor (pro-PPI) rapidly converted to omeprazole in the systemic circulation giving a prolonged residence time. AGN-201904 has been used in trials studying the prevention of peptic ulcer.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23672767
Created by
admin on Mon Mar 31 18:13:22 GMT 2025 , Edited by admin on Mon Mar 31 18:13:22 GMT 2025
|
PRIMARY | |||
|
651728-41-5
Created by
admin on Mon Mar 31 18:13:22 GMT 2025 , Edited by admin on Mon Mar 31 18:13:22 GMT 2025
|
PRIMARY | |||
|
14Y11U7IYM
Created by
admin on Mon Mar 31 18:13:22 GMT 2025 , Edited by admin on Mon Mar 31 18:13:22 GMT 2025
|
PRIMARY | |||
|
DTXSID40983747
Created by
admin on Mon Mar 31 18:13:22 GMT 2025 , Edited by admin on Mon Mar 31 18:13:22 GMT 2025
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
